通过SKI-178准SphK1/2可以抑制前列腺癌细胞的生长
1Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, China.
Cell death & disease
|August 21, 2023
概括
新型抑制剂SKI-178有效向斯芬戈酶 (SphK1/2),通过破坏线粒体功能和关键信号通路,显著减少前列腺癌细胞的生长和迁移在体外和体内.
科学领域:
- 在瘤学瘤学.
- 生物化学 生化学
- 分子生物学分子生物学
背景情况:
- 斯芬哥辛激酶 (SphK1和SphK2) 是关键的酶,与前列腺癌的进展有关.
- 在人类前列腺癌组织中观察到SphK1和SphK2的升级.
- 过度表达SphK1和SphK2促进前列腺癌细胞的增殖和迁移.
研究的目的:
- 为了评估SKI-178的抗前列腺癌活性,这是一种新的SphK1/2双抑制剂.
- 研究SKI-178对前列腺癌细胞影响的机制.
- 在前列腺癌异种移植模型中评估SKI-178的体内疗效.
主要方法:
- 生物信息学分析和检查人类前列腺癌组织.
- 在体外研究中使用原发性前列腺癌细胞和永生细胞系.
- 在体内研究涉及裸体小鼠PC-3异种移植模型.
主要成果:
- SKI-178显示出强大的抑制前列腺癌细胞活力,增殖,细胞循环进展和迁移.
- SKI-178诱导了显著的亡,线粒体功能受损 (脱极化,ROS产量,ATP耗尽),以及胺的产量增加.
- 在体内,SKI-178有效抑制PC-3异种移植瘤的生长,观察到SphK抑制,改变信号通路 (Akt-mTOR无活化,JNK激活),以及瘤组织的代谢干扰.
结论:
- 用SKI-178准SphK1/2是前列腺癌的一个有前途的治疗策略.
- SKI-178通过调节关键细胞通路和功能,在体外和体内都表现出强大的抗癌作用.
- 进一步调查SKI-178作为前列腺癌治疗药物是有必要的.
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K